Repurposing thalidomide derivatives to augment cancer immunotherapy [ 1/1/2021 - 12/31/2024 ]

Research Grant

Brief description Immunotherapies are a revolutionary approach for cancer treatment, but most people with cancer do not respond to therapy. We have identified a new set of molecular switches that shutdown immune function and limit responsiveness to existing immunotherapies. Importantly, we have found a class of approved drugs that can block these immune 'off switches'. This proposal will test if these drugs could be repurposed as a novel treatment to amplify the efficacy of existing immunotherapies.

Funding Amount $1,154,196

Funding Scheme Ideas Grants

Chief Investigator Dr Ian Parish

Notes Ideas Grants